WALTHAM,
Mass., Dec. 4, 2023 /PRNewswire/ -- Syndax
Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies,
today announced that the Company will host an in-person investor
event, along with a live webcast, on Monday,
December 11, 2023, at 7:00 a.m.
PT / 10:00 a.m. ET during the
65th American Society of Hematology (ASH) Annual Meeting
in San Diego, California.
The event will include new data for both the axatilimab and
revumenib programs, and members of the Syndax management team will
be joined by the following key opinion leaders:
- Daniel Wolff, M.D., Professor of
Hematology, Department of Internal Medicine III of the University
of Regensburg
- Eytan M. Stein, M.D., Chief,
Program for Drug Development in Leukemia, Department of Medicine,
Memorial Sloan Kettering Cancer Center
- Ghayas C. Issa, M.D., Assistant
Professor, Department of Leukemia, Division of Cancer Medicine, The
University of Texas MD Anderson Cancer
Center
- Joshua F. Zeidner, M.D.,
Associate Professor of Medicine, Chief, Leukemia Research,
University of North Carolina,
Lineberger Comprehensive Cancer Center
- Neerav N. Shukla, M.D., Chief,
Pediatric Translational Medicine Service, Memorial Sloan Kettering
Cancer Center
The live audio webcast and accompanying slides may be accessed
through the Events & Presentations page in the
Investors section of the Company's website or directly through the
meeting link here.
For those unable to participate in the conference call or
webcast, a replay will be available on the Investors section of the
Company's website at www.syndax.com for a limited
time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical
company developing an innovative pipeline of cancer therapies.
Highlights of the Company's pipeline include revumenib, a highly
selective inhibitor of the menin–KMT2A binding interaction, and
axatilimab, a monoclonal antibody that blocks the colony
stimulating factor 1 (CSF-1) receptor. For more information, please
visit www.syndax.com or follow the Company on
Twitter and LinkedIn.
Syndax Contacts
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
SNDX-G
View original
content:https://www.prnewswire.com/news-releases/syndax-to-host-investor-event-to-discuss-axatilimab-and-revumenib-data-updates-at-65th-ash-annual-meeting-302003796.html
SOURCE Syndax Pharmaceuticals, Inc.